Engineered immune cells take on advanced kidney cancer in new trial

NCT ID NCT06245915

Ongoing Disease control Sponsor: Arsenal Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests a new treatment called AB-2100 for people with advanced or metastatic clear-cell renal cell carcinoma that has come back after standard treatments. AB-2100 is made from the patient's own immune cells, which are modified in the lab to better recognize and attack cancer cells. The study aims to see if this therapy is safe and whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AB-2100 (a type of modified immune cell therapy called Integrated Circuit T cells)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced kidney cancer that has stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with only 37 participants, so results may not apply to everyone. The therapy may cause serious side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma Clear-cell metastatic renal cell carcinoma kidney cancer nonpapillary renal cell carcinoma Recurrence renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED/METASTATIC CLEAR CELL RENAL CELL CARCINOMA RECURRENCE

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Dana Farber Cancer Institue

Boston, Massachusetts, 02215, United States
Huntsman Cancer Institute - Univ of Utah Health

Salt Lake City, Utah, 84112, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Mayo Clinic Hospital

Phoenix, Arizona, 85054, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Perlmutter Cancer Center - NYU Langone Health

New York, New York, 10016, United States
University of Iowa and Holden Comprehensive Cancer Center

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.